The Dutch Initiative on Crohn and Colitis (ICC) Registry, a prospective multicentre analysis, reported that tofacitinib was still effective in achieving clinical remission of UC after anti-TNF and/or vedolizumab failure [25]. This evidence concerns the gene TNF and Crohn's colitis.